Revenue Update on AngioDynamics(NASDAQ:ANGO)

AngioDynamics(NASDAQ:ANGO) announced the earnings results for Fiscal Year 2017 and Q1. The results came in during Pre-market on Oct 5, 2016. Company reported revenue of $88.10M. Analysts estimated a revenue of $85.85M. Earnings per share were $0.17. Analysts had estimated an EPS of $0.13.

AngioDynamics (ANGO) made into the market gainers list on Fridays trading session with the shares advancing 0.41% or 0.07 points. Due to strong positive momentum, the stock ended at $17.07, which is also near the day’s high of $17.14. The stock began the session at $17.1 and the volume stood at 3,19,240 shares. The 52-week high of the shares is $17.64 and the 52 week low is $9.71. The company has a current market capitalization of $630 M and it has 3,68,84,124 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Aug 5, 2016, David F Burgstahler (director 10% owner) sold 2,250,000 shares at $14.62 per share price.Also, On May 9, 2016, Charles R Greiner (VP – Global Franchise) sold 3,508 shares at $12.31 per share price.On Apr 25, 2016, Stephen A Trowbridge (SVP and General Counsel) sold 12,940 shares at $12.26 per share price, according to the Form-4 filing with the securities and exchange commission.

AngioDynamics Inc. designs manufactures and sells a range of medical surgical and diagnostic devices used by professional healthcare providers for vascular access for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include fluid management venous thrombus management as well as other core products. The Company’s BioFlo products incorporate Endexo technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its microwave ablation products its radiofrequency ablation (RFA) and its NanoKnife product lines.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

AngioDynamics - Is it time to Sell?

Top Brokerage Firms are advising their investors on AngioDynamics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.